Company Reports / GlaxoSmithKline LTD.

COMPANY: GlaxoSmithKline LTD.

INDEX RANK: 7th

Total Impact Score: 620,529.06

GlaxoSmithKline LTD. is ranked 7th place in our index for 2015. GlaxoSmithKline LTD.’s drugs have a total impact score of 620,529.06. GlaxoSmithKline treats six diseases in our model - HIV, roundworm, hookworm, whipworm, LF, and P. falc malaria - with four total drugs - Albendazole (ALB), Atovaquone + Proguanil (AT + PG), Zidovudine (AZT), and Abacavir (ABC). GlaxoSmithKline receives credit for two treatments against HIV - Zidovudine (AZT) and Abacavir (ABC). These two drugs averted 375,309.79 of the total DALYS for HIV, which is 14.65% of the worldwide DALYs that we estimate would have been lost due to HIV in 2015 in the absence of effective treatment. GlaxoSmithKline’s drug portfolio placed it 4th in terms of total averted DALYs for HIV. GlaxoSmithKline receives credit for one treatment against roundworm - Albendazole (ALB). This one drug averted 281,499.93 of the total DALYS for roundworm, which is 77.00% of the worldwide DALYs that we estimate would have been lost due to roundworm in 2015 in the absence of effective treatment. GlaxoSmithKline’s drug portfolio placed it 1st in terms of total averted DALYs for roundworm. GlaxoSmithKline receives credit for treatments against hookworm - Albendazole (ALB). These drugs averted 24,366.12 of the total DALYS for hookworm, which is 87.88% of the worldwide DALYs that we estimate would have been lost due to hookworm in 2015 in the absence of effective treatment. GlaxoSmithKline’s drug portfolio placed it 1st in terms of total averted DALYs for hookworm. GlaxoSmithKline receives credit for one treatment against whipworm - Albendazole (ALB). This one drug averted 7,856.36 of the total DALYS for whipworm, which is 57.12% of the worldwide DALYs that we estimate would have been lost due to whipworm in 2015 in the absence of effective treatment. GlaxoSmithKline’s drug portfolio placed it 1st in terms of total averted DALYs for whipworm. GlaxoSmithKline receives credit for one treatment against LF - Albendazole (ALB). This one drug averted 2,484.03 of the total DALYS for LF, which is 50.00% of the worldwide DALYs that we estimate would have been lost due to LF in 2015 in the absence of effective treatment. GlaxoSmithKline’s drug portfolio placed it 1st in terms of total averted DALYs for LF. GlaxoSmithKline receives credit for one treatment against P. falc malaria - Atovaquone + Proguanil (AT + PG). This one drug averted 0 of the total DALYS for P. falc malaria, which is 0.00% of the worldwide DALYs that we estimate would have been lost due to P. falc malaria in 2015 in the absence of effective treatment. GlaxoSmithKline’s drug portfolio placed it 8th in terms of total averted DALYs for P. falc malaria.

Company Score Breakdown:

Key Drugs

ABACAVIR (ABC)

Abacavir (ABC) is an ARV drug recommended by the WHO as a part of the preferred first-line regimen to treat HIV in children less than 10 years old, as a part of an alternative first-line regimen in adolescents, and as part of the recommended regimen for children also being treated for TB. Major toxicity concerns include hypersensitivity reactions. The Wellcome Foundation Limited first patented Abacavir. It is now a part of GlaxoSmithKline, the current patent holder.

ALBENDAZOLE (ALB)

Albendazole (Alb) is used in many worm treatments and works by keeping the worms from absorbing sugar, which causes them to starve. Adverse effects include Transient gastrointestinal discomfort and headache, It was patented in 1975 by the Smithkline corporation. It is on the WHO’s list of essential medicines.

ATOVAQUONE-PROGUANIL (AT+PG)

Atovaquone-Proguanil (AT+PG) is a combination therapy used in the treatment and prophylaxis of P. falciparum malaria. The WHO recommends that AT+PG be used as a prophylactic drug, in combination with other antimalarials. The combination was patented by GlaxoSmithKline in 1999.

ZIDOVUDINE (AZT)

Zidovudine (AZT) is an ARV drug recommended by the WHO in the treatment of HIV as a part of alternative first-line regimens for adults, adolescents, and children older than three years, as a part of the preferred first-line regimen for children younger than three, and in the recommended treatments for children also being treated for TB, and in patients with HBV coinfection. Major toxicity concerns include severe anemia, neutropenia, and lactic acidosis. The first patent for Zidovudine was filed in 1999 by Glaxo, which is now a part of GlaxoSmithKline.

Company Information

GlaxoSmithKline is a global pharmaceutical company headquartered in Brentford, London, and founded in 2000 after the merger of GlaxoWellcome and SmithKline Beecham. They focus on the manufacture of HIV and respiratory-related pharmaceuticals, oral health, respiratory, pain relief consumer healthcare products, and a broad portfolio of vaccines. Viiv Healthcare, majority owned by GSK, along with Pfizer Inc., is a joint-venture pharmaceutical company focusing on advancing care and delivering treatment to HIV communities. Viiv’s approach to improving access to their current portfolio of 12 HIV medicines involves not applying for patents in LDCs or LICs, voluntary licensing (royalty-free) for all least developed, low-income, lower-middle income, and Sub-Saharan African countries, and providing at-cost pricing in LDCs, LICs and SSAs (until generics are available), while focusing their R&D to improve HIV care and prevention. One GSK program, in partnership with Medicine for Malaria Ventures, developed a new P. vivax malaria treatment, the only new treatment for this strain in the past 60 years. Key GSK products include Zentel®, Malarone® and Tivicay®. They have nearly 100,000 employees working in over 150 countries and a turnover of $39.7 billion in 2017.

Company Report PDF

CONTACT US © 2017 GLOBAL HEALTH IMPACT